PD-L1 inhibition with avelumab plus abiraterone acetate or enzalutamide in African Americans with metastatic castrate-resistant prostate cancer (mCRPC).

87Background: African Americans (AA) are at higher risk for prostate cancer death compared to other ethnic groups in the United States. Early immune-based therapy prolonged overall survival in men ...